Core Viewpoint - The significant surge of over 200% in the stock price of Sinovant Pharmaceuticals on its debut in the Hong Kong stock market is attributed to the market's high recognition of its first domestically produced long-acting GLP-1 receptor agonist and strong confidence in the vast potential of the weight loss drug market [1] Investment Opportunities - The rise of innovative drug sectors presents potential investment opportunities, as exemplified by the stock performance of Four Seasons Pharmaceuticals, which has increased nearly 150% this year, primarily due to the high growth of its medical aesthetics business [2] - The value of Four Seasons' innovative drug segment remains significantly underestimated, indicating further growth potential [2][5] Product Development - Four Seasons Pharmaceuticals' subsidiary, Huisheng Biopharma, has received acceptance for the market application of its long-acting GLP-1 receptor agonist, Semaglutide, for improving blood sugar control in type 2 diabetes patients, with its weight loss indication entering the follow-up phase of clinical trials [4] - Semaglutide's unique mechanism and clinical value position it as a key player in managing both blood sugar and weight, aligning with global treatment guidelines [6][10] Market Dynamics - The global diabetes and obesity epidemic presents a significant challenge, with the International Diabetes Federation projecting that the number of adults with diabetes will reach 589 million by 2024, with China having the highest number of patients [8] - Traditional treatment options are limited, making GLP-1 therapies a breakthrough direction for diabetes treatment and a key solution for metabolic diseases [10] Competitive Landscape - Huisheng Biopharma has established itself as a leading player in the diabetes treatment sector, with a comprehensive product matrix that includes nearly 20 approved drugs for diabetes and its complications [14] - The company operates a full industry chain model that enhances its ability to respond to market demands and ensures product quality and supply chain stability [16] Global Expansion - Huisheng Biopharma has made significant strides in global expansion, with partnerships in various countries to promote its diabetes medications, and has completed FDA registration for Semaglutide [16] Conclusion - The innovative drug segment of Four Seasons Pharmaceuticals is poised for continued growth, supported by a robust cash reserve of nearly 4 billion and the commercialization of key products like Semaglutide [17]

Core Viewpoint - The application for the market approval of Semaglutide injection by Huisheng Biopharmaceutical Co., Ltd., a non-wholly owned subsidiary of Sihuan Pharmaceutical (00460), has been accepted by the National Medical Products Administration (NMPA) for the treatment of blood sugar control in adult patients with type 2 diabetes [1] Group 1 - Semaglutide injection is a long-acting GLP-1 receptor agonist (GLP-1RA) that is administered once a week [1] - The drug enhances insulin secretion in a glucose-dependent manner, suppresses glucagon secretion, and delays gastric emptying, thereby lowering blood sugar levels [1] - The indication for weight loss has completed Phase III clinical enrollment and is currently in the follow-up stage [1] Group 2 - Semaglutide also reduces appetite and decreases food intake, helping patients to lower caloric intake and achieve weight loss [1]

Core Viewpoint - The application for the market approval of Semaglutide injection by Huisheng Biopharmaceutical Co., Ltd., a non-wholly owned subsidiary of Sihuan Pharmaceutical (00460.HK), has been accepted by the National Medical Products Administration (NMPA) for the treatment of adult patients with type 2 diabetes [1] Group 1: Product Development - Semaglutide injection is a long-acting GLP-1 receptor agonist (GLP-1RA) that is administered once a week, enhancing insulin secretion and suppressing glucagon secretion in a glucose-dependent manner, while also delaying gastric emptying to lower blood sugar levels [1] - The drug has also completed Phase III clinical enrollment for its weight loss indication and is currently in the follow-up stage [1] Group 2: Strategic Focus - The diabetes sector is a key focus area for Huisheng Biopharmaceutical, and the acceptance of the Semaglutide injection application marks a significant advancement in the drug's development process [1] - This progress is expected to enhance the core competitiveness of both Sihuan Pharmaceutical and Huisheng Biopharmaceutical in the diabetes treatment market [1]

智通财经APP讯，四环医药(00460)公布，该集团旗下非全资附属公司惠升生物制药股份有限公司开发的 司美格鲁肽注射液上市申请获得国家药品监督管理局(NMPA)受理，用于改善成人2型糖尿病患者的血糖 控制。此外，司美格鲁肽注射液用于减重的适应症已完成III期临床入组，处于随访阶段。 据悉，司美格鲁肽注射液是一周注射一次的长效GLP-1受体激动剂(GLP-1RA)，可通过启动GLP-1受 体，以葡萄糖浓度依赖的方式增强胰岛素分泌，抑制胰高血糖素分泌，并能够延缓胃排空，从而达到降 低血糖的作用;同时，司美格鲁肽可降低食欲和减少食物摄入量，帮助患者减少热量摄入，从而达到降 低体重的作用。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 – 1 – 根據國際糖尿病聯盟(IDF)最 新 數 據，2024年中國糖尿病患者人數為1.48億 人（佔 全 球25.1%），預 計 至2050年將增長至1.683億 人。據 諾 和 諾 德 財 報 數 據，2025年 上 半 年，諾 和 諾 德 的 司 美 格 魯 肽 注 射 液（糖 尿 病 適 應 症）銷 售 額 約645億丹麥克朗 （合101億 美 元，按1丹麥克朗≈ 0.1562美 元，下 同），同 比 增 長15%；司 美 格 魯 肽 注 射 液（減 重 適 應 症）銷 售 額 約369億 丹 麥 克 朗（合58億 美 元），同 比 增 長78%。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 惠升生物開發的司 ...

Core Viewpoint - Four Seasons Pharmaceutical (00460) experienced a 5.76% increase in stock price, reaching 1.47 CNY per share, with a trading volume of 95.36 million CNY as of August 13 [1] Group 1: Company Overview - Four Seasons Pharmaceutical Holdings Group Co., Ltd. is a leading pharmaceutical company in China's prescription drug market, primarily engaged in the production and sale of cardiovascular prescription drugs [1] - Since 2007, the company has been the largest supplier of cardiovascular prescription drugs in the country [1] - Key operational data includes a unique sales model, a nationwide sales network, a diversified product portfolio, and strong research and development capabilities [1] Group 2: Financial Performance - As of the 2024 annual report, Four Seasons Pharmaceutical reported total revenue of 1.901 billion CNY and a net loss of 217 million CNY [2]

本文源自：金融界 作者：行情君 8月4日，四环医药(00460)盘中上涨5.38%，截至13:19，报1.37元/股，成交7676.13万元。 四环医药控股集团有限公司是中国处方药市场的领先制药企业，主要业务为生产和销售心脑血管处方药 物，自2007年起一直是全国最大的心脑血管处方药物供应商。公司的关键经营数据包括独特的销售模 式、全国覆盖的销售网络、多元化的产品组合以及强大的研发能力。 截至2024年年报，四环医药营业总收入19.01亿元、净利润-2.17亿元。 ...

Core Viewpoint - Four Seasons Pharmaceutical (00460) has announced a positive earnings forecast, expecting revenue of no less than RMB 1.1 billion and net profit of no less than RMB 50 million for the six months ending June 30, 2025 [1] Financial Performance - The company anticipates significant growth in its medical aesthetics business, with a year-on-year growth rate between 50% and 60% [1] - The innovative drug segment is entering a harvest phase, characterized by reduced R&D expenses, a steady stream of new product approvals, and successful commercialization progress, leading to continuous revenue growth in this segment [1] - The decline in the generic drug business is narrowing year by year, indicating improved performance in this area [1] - The company's financial condition remains robust, with ample cash reserves on the balance sheet [1]

消息面上，近日，四环医药发盈喜，集团预期截至2025年6月30日止六个月内取得不低于人民币11亿元 的收入及不低于人民币5000万元的净利润。 公告称，影响集团于该期间内的财务业绩主要包括如下因素：医美业务高增长，相较于去年同期增速在 50%–60%之间；创新药业务进入收获期，包括创新药研发开支逐步减少，获批新产品持续涌现，新产 品的商业化进展顺利，该板块的分部收入持续增长；仿制药业务的下跌幅度逐年收窄；公司财务状况稳 健，账面现金充裕。 智通财经APP获悉，四环医药(00460)涨超3%，截至发稿，涨3.2%，报77.5港元，成交额2.35亿港元。 ...

Core Insights - The company expects to achieve revenue of no less than RMB 1.1 billion and net profit of no less than RMB 50 million for the six months ending June 30, 2025 [1] - The financial performance during this period is influenced by several factors, including significant growth in the medical aesthetics business, the maturation of innovative drug operations, a narrowing decline in the generic drug sector, and a strong financial position with ample cash reserves [1] Group 1 - The medical aesthetics business is projected to grow at a rate of 50%-60% compared to the same period last year [1] - The innovative drug segment is entering a harvest phase, with reduced R&D expenses, a steady stream of new product approvals, and successful commercialization efforts [1] - The decline in the generic drug business is narrowing year by year [1] - The company maintains a robust financial status with substantial cash on hand [1] Group 2 - From January 2024 to July 2025, the company has received approvals for 41 new medical aesthetics and pharmaceutical products, including nine medical aesthetics products and 32 pharmaceutical products [2] - Key products include self-developed medical devices and innovative drugs, which are expected to drive future revenue and profit growth [2] - The company is confident about its future development prospects due to the simultaneous launch of numerous significant new products [2]